High-Density Lipoproteins as Homeostatic Nanoparticles of Blood Plasma. 2020

Vasily A Kudinov, and Olga Yu Alekseeva, and Tatiana I Torkhovskaya, and Konstantin K Baskaev, and Rafael I Artyushev, and Irina N Saburina, and Sergey S Markin
Laboratory of Cell Biology and Developmental Pathology, FSBSI Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia.

It is well known that blood lipoproteins (LPs) are multimolecular complexes of lipids and proteins that play a crucial role in lipid transport. High-density lipoproteins (HDL) are a class of blood plasma LPs that mediate reverse cholesterol transport (RCT)-cholesterol transport from the peripheral tissues to the liver. Due to this ability to promote cholesterol uptake from cell membranes, HDL possess antiatherogenic properties. This function was first observed at the end of the 1970s to the beginning of the 1980s, resulting in high interest in this class of LPs. It was shown that HDL are the prevalent class of LPs in several types of living organisms (from fishes to monkeys) with high resistance to atherosclerosis and cardiovascular disorders. Lately, understanding of the mechanisms of the antiatherogenic properties of HDL has significantly expanded. Besides the contribution to RCT, HDL have been shown to modulate inflammatory processes, blood clotting, and vasomotor responses. These particles also possess antioxidant properties and contribute to immune reactions and intercellular signaling. Herein, we review data on the structure and mechanisms of the pleiotropic biological functions of HDL from the point of view of their evolutionary role and complex dynamic nature.

UI MeSH Term Description Entries
D008075 Lipoproteins, HDL A class of lipoproteins of small size (4-13 nm) and dense (greater than 1.063 g/ml) particles. HDL lipoproteins, synthesized in the liver without a lipid core, accumulate cholesterol esters from peripheral tissues and transport them to the liver for re-utilization or elimination from the body (the reverse cholesterol transport). Their major protein component is APOLIPOPROTEIN A-I. HDL also shuttle APOLIPOPROTEINS C and APOLIPOPROTEINS E to and from triglyceride-rich lipoproteins during their catabolism. HDL plasma level has been inversely correlated with the risk of cardiovascular diseases. High Density Lipoprotein,High-Density Lipoprotein,High-Density Lipoproteins,alpha-Lipoprotein,alpha-Lipoproteins,Heavy Lipoproteins,alpha-1 Lipoprotein,Density Lipoprotein, High,HDL Lipoproteins,High Density Lipoproteins,Lipoprotein, High Density,Lipoprotein, High-Density,Lipoproteins, Heavy,Lipoproteins, High-Density,alpha Lipoprotein,alpha Lipoproteins
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D006706 Homeostasis The processes whereby the internal environment of an organism tends to remain balanced and stable. Autoregulation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents
D000975 Antioxidants Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. Anti-Oxidant,Antioxidant,Antioxidant Activity,Endogenous Antioxidant,Endogenous Antioxidants,Anti-Oxidant Effect,Anti-Oxidant Effects,Anti-Oxidants,Antioxidant Effect,Antioxidant Effects,Activity, Antioxidant,Anti Oxidant,Anti Oxidant Effect,Anti Oxidant Effects,Anti Oxidants,Antioxidant, Endogenous,Antioxidants, Endogenous
D001692 Biological Transport The movement of materials (including biochemical substances and drugs) through a biological system at the cellular level. The transport can be across cell membranes and epithelial layers. It also can occur within intracellular compartments and extracellular compartments. Transport, Biological,Biologic Transport,Transport, Biologic

Related Publications

Vasily A Kudinov, and Olga Yu Alekseeva, and Tatiana I Torkhovskaya, and Konstantin K Baskaev, and Rafael I Artyushev, and Irina N Saburina, and Sergey S Markin
January 1979, Bulletin de l'Academie nationale de medecine,
Vasily A Kudinov, and Olga Yu Alekseeva, and Tatiana I Torkhovskaya, and Konstantin K Baskaev, and Rafael I Artyushev, and Irina N Saburina, and Sergey S Markin
November 1978, The New England journal of medicine,
Vasily A Kudinov, and Olga Yu Alekseeva, and Tatiana I Torkhovskaya, and Konstantin K Baskaev, and Rafael I Artyushev, and Irina N Saburina, and Sergey S Markin
April 1979, The New England journal of medicine,
Vasily A Kudinov, and Olga Yu Alekseeva, and Tatiana I Torkhovskaya, and Konstantin K Baskaev, and Rafael I Artyushev, and Irina N Saburina, and Sergey S Markin
January 1971, Biochemical Society symposium,
Vasily A Kudinov, and Olga Yu Alekseeva, and Tatiana I Torkhovskaya, and Konstantin K Baskaev, and Rafael I Artyushev, and Irina N Saburina, and Sergey S Markin
March 2016, ACS nano,
Vasily A Kudinov, and Olga Yu Alekseeva, and Tatiana I Torkhovskaya, and Konstantin K Baskaev, and Rafael I Artyushev, and Irina N Saburina, and Sergey S Markin
March 1965, The Journal of clinical investigation,
Vasily A Kudinov, and Olga Yu Alekseeva, and Tatiana I Torkhovskaya, and Konstantin K Baskaev, and Rafael I Artyushev, and Irina N Saburina, and Sergey S Markin
January 1981, Voprosy meditsinskoi khimii,
Vasily A Kudinov, and Olga Yu Alekseeva, and Tatiana I Torkhovskaya, and Konstantin K Baskaev, and Rafael I Artyushev, and Irina N Saburina, and Sergey S Markin
January 1974, Scandinavian journal of clinical and laboratory investigation. Supplementum,
Vasily A Kudinov, and Olga Yu Alekseeva, and Tatiana I Torkhovskaya, and Konstantin K Baskaev, and Rafael I Artyushev, and Irina N Saburina, and Sergey S Markin
January 1982, CRC critical reviews in biochemistry,
Vasily A Kudinov, and Olga Yu Alekseeva, and Tatiana I Torkhovskaya, and Konstantin K Baskaev, and Rafael I Artyushev, and Irina N Saburina, and Sergey S Markin
January 1978, Voprosy meditsinskoi khimii,
Copied contents to your clipboard!